US 12,064,403 B2
Targeting PAX2 for the treatment of breast cancer
Carlton D. Donald, Atlanta, GA (US)
Filed by PHIGENIX, INC., Atlanta, GA (US)
Filed on Mar. 2, 2021, as Appl. No. 17/189,525.
Application 17/189,525 is a continuation of application No. 14/464,565, filed on Aug. 20, 2014, granted, now 11,033,628.
Application 14/464,565 is a continuation of application No. 13/116,752, filed on May 26, 2011, abandoned.
Application 13/116,752 is a continuation of application No. 12/708,294, filed on Feb. 18, 2010, granted, now 8,080,534, issued on Dec. 20, 2011.
Application 12/708,294 is a continuation in part of application No. 12/090,191, granted, now 7,964,577, issued on Jun. 21, 2011, previously published as PCT/US2006/040215, filed on Oct. 16, 2006.
Claims priority of provisional application 60/726,921, filed on Oct. 14, 2005.
Prior Publication US 2021/0213136 A1, Jul. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/138 (2006.01); A61K 31/145 (2006.01); A61K 31/352 (2006.01); A61K 31/40 (2006.01); A61K 31/41 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/437 (2006.01); A61K 31/7056 (2006.01); A61K 31/7088 (2006.01); A61K 38/08 (2019.01); A61K 38/48 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); C07K 16/18 (2006.01); C12N 15/113 (2010.01); A61K 39/00 (2006.01); C12Q 1/68 (2018.01)
CPC A61K 31/138 (2013.01) [A61K 31/145 (2013.01); A61K 31/352 (2013.01); A61K 31/40 (2013.01); A61K 31/41 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/437 (2013.01); A61K 31/7056 (2013.01); A61K 31/7088 (2013.01); A61K 38/085 (2013.01); A61K 38/48 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6807 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); C07K 16/18 (2013.01); C12N 15/113 (2013.01); A61K 2039/505 (2013.01); C12N 2310/14 (2013.01); C12N 2310/351 (2013.01); C12N 2310/50 (2013.01)] 20 Claims
 
1. A method of treating breast cancer in a subject, comprising:
administering to the subject an anti-PAX2 composition,
wherein the composition comprises an effective amount of an anti-PAX2 agent,
wherein the anti-PAX2 agent is an antagonist of PAX2; and
wherein the anti-PAX2 agent is not a STAT3 inhibitor.